Literature DB >> 9242376

DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene.

J L Kissil1, E Feinstein, O Cohen, P A Jones, Y C Tsai, M A Knowles, M E Eydmann, A Kimchi.   

Abstract

DAP-kinase is a novel calmodulin dependent serine/threonine kinase that carries ankyrin repeats and the death domain. It was recently isolated, by a functional selection approach of gene cloning, as a positive mediator of programmed cell death. In this study the expression of DAP-kinase was examined in the cell lines derived from various human neoplasms. DAP-kinase mRNA and protein expression were below the limit of detection in eight out of ten neoplastic derived B-cell lines. In six out of 14 examined bladder carcinoma, in three out of five renal cell carcinoma, and in four out of ten tested breast carcinoma cell lines, the DAP-kinase protein levels were below detection limits or lower than 1% compared to the positive cell lines. Interestingly, DAP-kinase expression could be restored in some of the negative bladder carcinoma and B-cell lines by treatment of cells with 5'-azadeoxycytidine that causes DNA demethylation. The high frequency of loss of DAP-kinase expression in human tumor cell lines, and the occasional involvement of methylation in this process raise the possibility that this novel mediator of cell death may function as a tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242376     DOI: 10.1038/sj.onc.1201172

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  DAP kinase and DAP-3: novel positive mediators of apoptosis.

Authors:  A Kimchi
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Resistance to apoptosis induced by microenvironmental stresses is correlated with metastatic potential in Lewis lung carcinoma.

Authors:  M Takasu; Y Tada; J O Wang; M Tagawa; K Takenaga
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

Review 3.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

Review 4.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

5.  A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.

Authors:  Nicholas T Hertz; Amandine Berthet; Martin L Sos; Kurt S Thorn; Al L Burlingame; Ken Nakamura; Kevan M Shokat
Journal:  Cell       Date:  2013-08-15       Impact factor: 41.582

6.  Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation.

Authors:  Melinda A Biernacki; Yu-tzu Tai; Guang Lan Zhang; Anselmo Alonso; Wandi Zhang; Rao Prabhala; Li Zhang; Nikhil Munshi; Donna Neuberg; Robert J Soiffer; Jerome Ritz; Edwin P Alyea; Vladimir Brusic; Kenneth C Anderson; Catherine J Wu
Journal:  Blood       Date:  2012-01-20       Impact factor: 22.113

7.  Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis.

Authors:  B Inbal; G Shani; O Cohen; J L Kissil; A Kimchi
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

8.  Genetic synthetic lethality screen at the single gene level in cultured human cells.

Authors:  A H Simons; N Dafni; I Dotan; Y Oron; D Canaani
Journal:  Nucleic Acids Res       Date:  2001-10-15       Impact factor: 16.971

9.  A role for DRAK2 in the germinal center reaction and the antibody response.

Authors:  Ahmed Al-Qahtani; Zhenming Xu; Hong Zan; Craig M Walsh; Paolo Casali
Journal:  Autoimmunity       Date:  2008-08       Impact factor: 2.815

10.  Death-associated protein kinase-mediated cell death modulated by interaction with DANGER.

Authors:  Bingnan N Kang; Abdullah S Ahmad; Sofiyan Saleem; Randen L Patterson; Lynda Hester; Sylvain Doré; Solomon H Snyder
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.